# Silence Therapeutics Plc American Depository Share (SLN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $14.59, market value $907 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Silence Therapeutics Plc American Depository Share reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 1474.5×**. Each dollar of revenue is priced at 1474.5×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 17.9×**. The shares trade at 17.9× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -4.7%** (5-yr avg -5.2%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 85.9%**. Silence Therapeutics Plc American Depository Share keeps 85.9% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Return on equity: -142.2%**. Return on equity is negative because earnings are negative.
- **Return on assets: -45.6%**. Each dollar of assets produces -45.6% of profit.

## Growth
- **Revenue growth (1 yr): -98.7%** (3-yr -70.4%/yr). Revenue fell 98.7% over the last year.
- **EPS growth (1 yr): -90.9%**. Earnings per share fell 90.9%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 8.72** (quick 8.72). Current assets cover the next year's liabilities 8.72 times.
- **Altman Z-score: 7.21**. A Z-score of 7.21 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Silence Therapeutics Plc American Depository Share does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (6 analysts). 6 analysts cover Silence Therapeutics Plc American Depository Share; the consensus is buy, with an average price target of $33.00 (+126% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 179.0%** (YTD 140.0%, 3-mo 136.5%). The shares are up 179.0% over twelve months including dividends.
- **From 52-week high: -17.0%** (248.2% above the low). Trading 17% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 64**. An RSI of 64 is neutral.
- **Beta (1 yr): 1.45** (volatility 86%). Beta of 1.45 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SLN · Page: https://foliofundamentals.com/stocks/sln

Not investment advice.